Lung Cancer

Vishal Vashistha, MD, a Duke medical oncology fellow, is first author of "Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program" (Abstract 2005) He will deliver an oral presentation on the study at the Care Delivery and Regulatory Policy Session May 29. Per the study abstract conclusions: "A substantial minority of patients with advanced NSCLC bearing highly-actionable gene variants are not prescribed available targeted agents. Further provider- and pathologist-directed educational effort are needed, as well as implementation of health informatics systems to provide near real-time decision support for test ordering and interpretation."
AUTHOR(S): Vishal Vashistha, Jenna Armstrong, David Winski, Meghan Price, Bradley J. Hintze, Pradeep Poonnen, Jane Snowdon, Gretchen Purcell Jackson, Dilhan Weeraratne, David Brotman, Neil L. Spector, Michael J. Kelley
 

ABSTRACTS

*Duke authors bolded

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
SESSION
Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Natasha B. Leighl, Mary Weber Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, James Lloyd Wade, William Johnson Irvin, Sreekanth Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Tom Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Vassiliki Papadimitrakopoulou, Karen Kelly
ABSTRACT / POSTER 9623 ● 389

AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
SESSION
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
AUTHOR(S)
Helen J. Ross, David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, Katja Schulze, JaneMichelle Michelle Brockman, Xiaofei F. Wang, Junheng Gao, Everett E. Vokes, Tom Stinchcombe
ABSTRACT / POSTER 9045 ● 238

Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).
SESSION
Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Joao Victor Machado Alessi, Carolyn Glass, Biagio Ricciuti, Liam F. Spurr, Lynette M. Sholl, Mark M. Awad
ABSTRACT / POSTER 9577 ● 343

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.
SESSION
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
AUTHOR(S)
Helen J. Ross, Chen Hu, Kristin Ann Higgins, Salma K. Jabbour, David E. Kozono, Taofeek Kunle Owonikoko, Benjamin Movsas, Timothy Solberg, Canhua Xiao, Terence Marques Williams, James William Welsh, Jeffry Simko, Xiaofei F. Wang, Nisha Anjali Mohindra, Charles Hsu, Tom Stinchcombe, Jeffrey Bradley
ABSTRACT / POSTER TPS9082 ● 275

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
SESSION
Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Xiuning Le, Jonathan Wade Goldman, Jeffrey Melson Clarke, Nishan Tchekmedyian, Zofia Piotrowska, David Chu, Gajanan Bhat, Francois M. Lebel, Mark A. Socinski
ABSTRACT / POSTER 9514 ● 280

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
SESSION
Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Andreas Nicholas Saltos, Tawee Tanvetyanon, Ben C. Creelan, Michael Rahman Shafique, Scott Joseph Antonia, Eric B. Haura, Hong Zheng, Margaret Barlow, James Saller, Anna Castellano-Fornelli, Antoine Richards, Ram Thapa, Theresa A. Boyle, Dung-Tsa Chen, Amer A Beg, Jhanelle Elaine Gray
ABSTRACT / POSTER 9567 ● 333

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
SESSION
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
AUTHOR(S)
Joseph W. Kim, Navid Hafez, Hatem Hussein Soliman, Siqing Fu, Shumei Kato, Primo Lara, Ulka N. Vaishampayan, Albiruni Ryan Abdul Razak, Dana Backlund Cardin, Pamela N. Munster, Joseph Paul Eder, Elizabeth M. Swisher, Andrew B. Nixon, Abhijit Patel, Yu Shyr, S. Percy Ivy, Patricia LoRusso
ABSTRACT / POSTER 9065 ● 258

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
SESSION
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
AUTHOR(S)
Jacob Sands, Sumithra J. Mandrekar, Geoffrey R. Oxnard, David E. Kozono, Shauna L Hillman, Suzanne Eleanor Dahlberg, Zhuoxin Sun, Jamie E. Chaft, Ramaswamy Govindan, David E. Gerber, Jhanelle Elaine Gray, Shakun M. Malik, Margaret M. Mooney, Pasi A. Janne, Everett E. Vokes, Karen Kelly, Suresh S. Ramalingam, Tom Stinchcombe
ABSTRACT / POSTER TPS9077 ● 270

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.
SESSION
Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Justin F. Gainor, Jeffrey Gary Schneider, Martin Gutierrez, James Michael Orcutt, Gene Grant Finley, Gregory Alan Otterson, Igor I. Rybkin, Pavan S. Reddy, Leora Horn, Julie R. Brahmer, Bruno R. Bastos, Mark M. Awad, Matthew David Hellmann, Suresh S. Ramalingam, Neal E. Ready, David R. Spigel, Ravi S. Kasinathan, Cécile Dorange, Hossein Borghaei
ABSTRACT / POSTER 9560 ● 326

Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).
SESSION
Publication Only: Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Jeffrey Melson Clarke, Xiaofei F. Wang, Lin Gu, Marvaretta Miesha Stevenson, Tom Stinchcombe, Sundhar Ramalingam, Scott Joseph Antonia, Afreen Shariff, Jennifer Garst, Jeffrey Crawford, Neal E. Ready
ABSTRACT e21683

Interferon gamma resistance in setting of LKB1 loss: Phenotypic characterization and investigation of mechanism.
SESSION
Publication Only: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
AUTHOR(S)
Jacob Kaufman
ABSTRACT e21015

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
SESSION
Publication Only: Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Suresh S. Ramalingam, Tom Stinchcombe, Gregory James Gerstner, Missak Haigentz, Surya Vangala, Megan Parsi, John W. Heyburn, Victor Kabala, Tuhina Prasad, Andres A. Gutierrez, Jonathan Wade Goldman, ADXS-503 Author's Group
ABSTRACT e21682

Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.
SESSION
Health Services Research and Quality Improvement
AUTHOR(S)
Pradeep Poonnen, Olivia Dong, David Winski, Shelby D. Reed, Vishal Vashistha, Jill S. Bates, Michael J. Kelley, Deepak Voora
ABSTRACT / POSTER 7075 ● 347

Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.
SESSION
Publication Only: Health Services Research and Quality Improvement
AUTHOR(S)
Christina D Williams, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael J. Kelley
ABSTRACT e19295